Back to Search
THOMAS FILE, MD
MD
Infectious Disease Physician
NPI: 1366529091Individual
Specialties, Licenses & Credentials
Infectious Disease PhysicianPrimary
Internal Medicine — Infectious Disease
Code: 207RI0200X
35038143(OH)
Research & Publications (20)
The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adults.
PMID 18029151·Int J Antimicrob Agents·2007
3-trial
Impact of community-acquired methicillin-resistant Staphylococcus aureus in the hospital setting.
PMID 17847173·Cleve Clin J Med·2007
6-review
Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
PMID 17537866·J Antimicrob Chemother·2007
4-observational
Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia.
PMID 16669927·Clin Microbiol Infect·2006
6-review
Community-associated methicillin-resistant Staphylococcus aureas: not only a cause of skin infections, also a new cause of pneumonia.
PMID 15735415·Curr Opin Infect Dis·2005
6-review
Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
PMID 15664480·Int J Antimicrob Agents·2005
3-trial
Gemifloxacin: a new, potent fluoroquinolone for the therapy of lower respiratory tract infections.
PMID 15566328·Expert Rev Anti Infect Ther·2004
6-review
Antimicrobial therapy of community-acquired pneumonia.
PMID 15555836·Infect Dis Clin North Am·2004
6-review
Streptococcus pneumoniae and community-acquired pneumonia: a cause for concern.
PMID 15360096·Am J Med·2004
6-review
Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults.
PMID 15328092·Antimicrob Agents Chemother·2004
3-trial
Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate.
PMID 12385678·Int J Antimicrob Agents·2002
3-trial
Rational use of antibiotics to treat respiratory tract infections.
PMID 12212759·Am J Manag Care·2002
8-other
Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of beta-lactam-resistant Streptococcus pneumoniae.
PMID 11810607·Clin Infect Dis·2002
6-review
Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin.
PMID 11474633·J Antimicrob Chemother·2001
3-trial
Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. The 070 Clinical Study group.
PMID 10949981·J Chemother·2000
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 75 ARCH ST, SUITE 105
AKRON, OH 44304 - Phone
- (330) 375-3894
Quick Facts
- NPI
- 1366529091
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile